{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:01:07Z","timestamp":1793840467922,"version":"4.6.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic\/refractory immune thrombocytopenia (ITP) is a rare and pathophysiologically heterogeneous disorder with variable responsiveness to available treatments. Sutimlimab, a first-in-class humanized monoclonal anti-C1s IgG4 antibody, selectively inhibits the classical pathway. This phase 1 study (NCT03275454) assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of biweekly sutimlimab in patients with chronic\/refractory ITP with an inadequate response to \u22652 therapies (platelet count \u2264\u00a030\u00a0\u00d7\u00a0109\/L). Twelve patients (median age 42 years) received sutimlimab for a median of 20.5 weeks followed by a median 2-week washout period (part A). In part B, 7 of the 12 eligible patients received sutimlimab retreatment for a median of 113 weeks. In part A, the mean (standard deviation) platelet count increased from 25\u00a0\u00d7 109\/L (17) to 54\u00a0\u00d7 109\/L (60) 24 hours after starting sutimlimab, maintaining \u226550\u00a0\u00d7 109\/L throughout part A. Five patients (42%) achieved durable platelet count responses (\u226550\u00a0\u00d7 109\/L in \u226550% of follow-up visits) and 4\u00a0achieved complete response (platelet count \u2265100\u00a0\u00d7 109\/L). The mean platelet count returned to baseline during washout and increased upon retreatment in part B. The mean platelet count improvements accompanied the rapid inhibition of the classical pathway. There were 74 treatment-emergent adverse events in part A (n\u00a0= 10) and 70 in part B (n\u00a0= 6). Five serious adverse events were observed; 1 event (migraine) was assessed by the investigator as related to sutimlimab. These results demonstrated that in some patients with ITP, autoantibodies activate the classical complement pathway, accelerating platelet destruction or impairing platelet production and contributing to treatment failure. Thus, C1s inhibition may be a safe and beneficial therapeutic approach for patients with chronic\/refractory ITP.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006864","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T16:12:15Z","timestamp":1660666335000},"page":"987-996","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia"],"prefix":"10.1182","volume":"7","author":[{"given":"Catherine M.","family":"Broome","sequence":"first","affiliation":[{"name":"1Division of Hematology, MedStar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-8810","authenticated-orcid":false,"given":"David J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"4Department of Haematology, University College London Hospitals, Cardiometabolic Program, National Institute for Health Research UCLH\/UCL Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Smith","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[{"name":"6Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reuter","sequence":"additional","affiliation":[{"name":"6Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hobbs","sequence":"additional","affiliation":[{"name":"6Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Daak","sequence":"additional","affiliation":[{"name":"6Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"4","key":"2023081516043943200_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1538-7836.2008.02911.x","article-title":"Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal","volume":"6","author":"Feudjo-Tepie","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2023081516043943200_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"26","key":"2023081516043943200_bib3","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"key":"2023081516043943200_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PROM.S140932","article-title":"Immune thrombocytopenia: improving quality of life and patient outcomes","volume":"9","author":"Trotter","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"2023081516043943200_bib5","first-page":"16","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"2023081516043943200_bib6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41598-018-38086-1","article-title":"Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia","volume":"9","author":"Grodzielski","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"2023081516043943200_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"Mahevas","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2023081516043943200_bib8","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2023081516043943200_bib9","doi-asserted-by":"crossref","first-page":"e0198184","DOI":"10.1371\/journal.pone.0198184","article-title":"Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice","volume":"13","author":"Depre","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"2023081516043943200_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2023081516043943200_bib11","first-page":"20","article-title":"Complement blockade with C1 esterase inhibitor in refractory immune thrombocytopenia","volume":"12","author":"Roesch","year":"2016","journal-title":"Am J Hematol Oncol"},{"issue":"6","key":"2023081516043943200_bib12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2023081516043943200_bib13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","article-title":"Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura","volume":"148","author":"Peerschke","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2023081516043943200_bib14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2023081516043943200_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A\u00a0randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"2023081516043943200_bib16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023081516043943200_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/pbc.23112","article-title":"Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population","volume":"58","author":"Grace","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"2023081516043943200_bib18","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"key":"2023081516043943200_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fimmu.2015.00317","article-title":"Emerging and novel functions of complement protein C1q","volume":"6","author":"Kouser","year":"2015","journal-title":"Front Immunol"},{"key":"2023081516043943200_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Hematol"},{"key":"2023081516043943200_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719873321","article-title":"Novel insights into the treatment of complement-mediated hemolytic anemias","volume":"10","author":"Berentsen","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"suppl 1","key":"2023081516043943200_bib22","article-title":"Inhibition of the classical pathway of complement with sutimlimab in chronic immune thrombocytopenic purpura patients without adequate response to two or more prior therapies [abstract]","volume":"134","author":"Broome","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023081516043943200_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-139663","article-title":"Long-term safety and efficacy of sutimlimab in patients with chronic immune thrombocytopenia [abstract]","volume":"136","author":"Broome","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/6\/987\/2071682\/blooda_adv-2021-006864-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/6\/987\/2071682\/blooda_adv-2021-006864-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T12:22:14Z","timestamp":1692102134000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/6\/987\/486249\/Safety-and-efficacy-of-classical-complement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006864","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]}}}